New Drug Combo Targets Fat Loss While Protecting Muscle Mass in GLP-1 Users
Metashape Pharma's MS 001 paired with semaglutide shows fat-selective weight loss and muscle preservation in preclinical mouse studies.
Summary
A small biotech company is developing a pill designed to work alongside popular GLP-1 drugs like Ozempic to improve how the body loses weight. The compound, called MS 001, aims to target fat specifically while protecting muscle — a major concern with current GLP-1 medications, which can cause significant muscle loss alongside fat. Early animal studies in obese mice showed that combining low doses of MS 001 with semaglutide increased calorie-burning thermogenesis, reduced fat selectively, and preserved lean muscle mass. The data will be presented at the American Diabetes Association's 2026 Scientific Sessions in June. While still in early preclinical stages, this approach addresses one of the most pressing limitations of GLP-1 therapy for long-term health and longevity.
Detailed Summary
One of the most significant drawbacks of GLP-1 receptor agonists like semaglutide — among the most widely used weight-loss drugs today — is that they can cause substantial muscle loss alongside fat reduction. For longevity-focused individuals, preserving muscle mass is critical, as it is strongly linked to metabolic health, mobility, and lifespan. Metashape Pharma is developing MS 001 specifically to address this problem.
MS 001, chemically known as ulodesine hemiglutarate, is an oral purine nucleoside phosphorylase (PNP) inhibitor. It is being developed as a small-molecule co-therapy intended to be taken alongside GLP-1 drugs to make weight loss more selective — burning fat while sparing lean tissue. The compound is currently in pre-IND development, meaning it has not yet entered formal clinical trials.
In preclinical studies using diet-induced obese mice, combining low-dose MS 001 with semaglutide produced three notable effects: increased thermogenesis (the body generating more heat and burning more calories), selective fat loss, and preservation of muscle mass. These results suggest the combination may improve the quality of weight loss compared to GLP-1 therapy alone.
The new data will be presented at the American Diabetes Association 2026 Scientific Sessions in New Orleans, with presentations scheduled for June 7 and 8. The abstract remains under embargo until June 5, 2026, after which full details will be published in the journal Diabetes.
For health-conscious adults using or considering GLP-1 medications, this research points toward a potentially important adjunct therapy. However, all findings are currently from animal models, and significant development milestones — including human safety and efficacy trials — remain ahead. The concept of fat-selective weight loss with muscle preservation is highly relevant to healthspan optimization, but clinical validation is still years away.
Key Findings
- MS 001 combined with semaglutide preserved muscle mass in obese mice, addressing a key GLP-1 side effect.
- The combination increased thermogenesis, suggesting enhanced calorie burning beyond GLP-1 alone.
- Fat loss was selective, meaning lean tissue was spared — critical for metabolic and longevity outcomes.
- MS 001 is an oral pill in early pre-IND stage, not yet in human clinical trials.
- Data will be presented at ADA 2026 Scientific Sessions and published in the journal Diabetes.
Methodology
This is a news report summarizing a company press release about preclinical research. The findings have not yet been peer-reviewed or published; the abstract remains under embargo. Evidence is based on animal (mouse) studies only, which limits direct applicability to humans.
Study Limitations
All data are from preclinical mouse models and have not been peer-reviewed or published yet. Human pharmacokinetics, safety, and efficacy are entirely unknown at this stage. Investors and health consumers should treat this as early-stage exploratory research, not actionable clinical guidance.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.